Filament Health Corp. announced that it has entered into a licensing agreement with Cybin Therapeutics (‘CT'). Under the agreement, Filament will license PEX010, its botanical psilocybin drug candidate, to CT for two upcoming Phase II clinical trials addressing depression and alcohol use disorder with an additional two planned for 2022.

The financial terms were not disclosed. CT filed a Clinical Trial Application (CTA) to Health Canada for the first trial in 2021, and anticipates its depression study to begin in the second quarter of 2022. Both trials will be led by Dr. Reg Peters and Dave Phillips.

Dr. Reg Peters has been involved in advocacy for compassionate use of psilocybin for palliative patients, including as a medical advisor to Therapsil. Mr. Dave Phillips, Training Advisor to Therapsil and a highly experienced psilocybin-assisted therapist, will lead the therapy component of the trials along with an experienced clinical team at Cybin Therapeutics' purpose-built clinic.